Clinical Trial Update: Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating sacituzumab govitecan in combination with toripalimab for resectable stage II-IIIB non-small cell lung cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Status: NOT_YET_RECRUITING